
1. lancet infect dis. 2019 sep;19(9):952-961. doi: 10.1016/s1473-3099(19)30391-3.
epub 2019 jul 22.

determinants dihydroartemisinin-piperaquine treatment failure plasmodium
falciparum malaria cambodia, thailand, vietnam: prospective clinical,
pharmacological, genetic study.

van der pluijm rw(1), imwong m(2), chau nh(3), hoa nt(3), thuy-nhien nt(3), thanh
nv(3), jittamala p(4), hanboonkunupakarn b(5), chutasmit k(6), saelow c(6),
runjarern r(7), kaewmok w(7), tripura r(1), peto tj(1), yok s(8), suon s(9),
sreng s(9), mao s(10), oun s(11), yen s(11), amaratunga c(12), lek d(13), huy
r(9), dhorda m(14), chotivanich k(5), ashley ea(15), mukaka m(1), waithira n(1), 
cheah py(1), maude rj(16), amato r(17), pearson rd(18), gonçalves s(17), jacob
cg(17), hamilton wl(17), fairhurst rm(12), tarning j(1), winterberg m(1),
kwiatkowski dp(18), pukrittayakamee s(19), hien tt(20), day np(1), miotto o(21), 
white nj(1), dondorp am(22).

author information: 
(1)mahidol oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, united
kingdom.
(2)mahidol oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand; department molecular tropical medicine 
and genetics, faculty tropical medicine, mahidol university, bangkok,
thailand.
(3)oxford university clinical research unit, hospital tropical diseases, ho
chi minh city, vietnam.
(4)mahidol oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand; department tropical hygiene, faculty of
tropical medicine, mahidol university, bangkok, thailand.
(5)mahidol oxford tropical medicine research unit, faculty tropical medicine, 
mahidol university, bangkok, thailand; department clinical tropical medicine, 
faculty tropical medicine, mahidol university, bangkok, thailand.
(6)phu sing hospital, phu sing, thailand.
(7)khun han hospital, khun han, thailand.
(8)pailin provincial health department, pailin, cambodia.
(9)national center parasitology, entomology malaria control, phnom penh, 
cambodia.
(10)sampov meas referral hospital, pursat, cambodia.
(11)ratanakiri referral hospital, ratanakiri, cambodia.
(12)laboratory malaria vector research, national institute allergy 
infectious diseases, national institutes health, rockville, md, usa.
(13)national center parasitology, entomology malaria control, phnom penh,
cambodia; school public health, national institute public health, phnom
penh, cambodia.
(14)mahidol oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, united
kingdom; worldwide antimalarial resistance network asia regional centre, bangkok,
thailand.
(15)centre tropical medicine global health, nuffield department of
medicine, university oxford, oxford, united kingdom; lao-oxford-mahosot
hospital wellcome trust research unit, vientiane, laos.
(16)mahidol oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, united
kingdom; harvard h chan school public health, harvard university, boston,
ma, usa.
(17)wellcome sanger institute, hinxton, united kingdom.
(18)wellcome sanger institute, hinxton, united kingdom; mrc centre genomics
and global health, big data institute, university oxford, oxford, uk.
(19)mahidol oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; department clinical tropical medicine, 
faculty tropical medicine, mahidol university, bangkok, thailand; royal
society thailand, dusit, bangkok, thailand.
(20)centre tropical medicine global health, nuffield department of
medicine, university oxford, oxford, united kingdom; oxford university
clinical research unit, hospital tropical diseases, ho chi minh city,
vietnam.
(21)mahidol oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, united
kingdom; wellcome sanger institute, hinxton, united kingdom; mrc centre for
genomics global health, big data institute, university oxford, oxford, uk.
(22)mahidol oxford tropical medicine research unit, faculty tropical medicine,
mahidol university, bangkok, thailand; centre tropical medicine global
health, nuffield department medicine, university oxford, oxford, united
kingdom. electronic address: arjen@tropmedres.ac.

comment in
    lancet infect dis. 2019 sep;19(9):916-917.
    lancet infect dis. 2019 nov;19(11):1167-1168.
    lancet infect dis. 2019 nov;19(11):1168-1169.
    lancet infect dis. 2020 jan;20(1):26-27.

background: emergence spread resistance plasmodium falciparum
malaria artemisinin combination therapies greater mekong subregion
poses major threat malaria control elimination. current study is
part multi-country, open-label, randomised clinical trial (tracii, 2015-18) 
evaluating efficacy, safety, tolerability triple artemisinin
combination therapies. high rate treatment failure treatment with
dihydroartemisinin-piperaquine observed thailand, cambodia, vietnam.
the immediate public health importance findings prompted us report 
efficacy data dihydroartemisinin-piperaquine determinants ahead the
results overall trial, published later year.
methods: patients aged 2 65 years presenting uncomplicated p
falciparum mixed species malaria seven sites thailand, cambodia, and
vietnam randomly assigned receive dihydroartemisinin-piperaquine 
without mefloquine, part tracii trial. primary outcome the
pcr-corrected efficacy day 42. next-generation sequencing used assess
the prevalence molecular markers associated artemisinin resistance
(kelch13 mutations, particular cys580tyr) piperaquine resistance
(plasmepsin-2 plasmepsin-3 amplifications crt mutations). study is
registered clinicaltrials.gov, number nct02453308.
findings: sept 28, 2015, jan 18, 2018, 539 patients acute p
falciparum malaria screened eligibility, 292 enrolled, 140
received dihydroartemisinin-piperaquine. overall kaplan-meier estimate of
pcr-corrected efficacy dihydroartemisinin-piperaquine day 42 50·0% (95%
ci 41·1-58·3). pcr-corrected efficacies individual sites 12·7%
(2·2-33·0) northeastern thailand, 38·2% (15·9-60·5) western cambodia, 73·4%
(57·0-84·3) ratanakiri (northeastern cambodia), 47·1% (33·5-59·6) binh 
phuoc (southwestern vietnam). treatment failure associated independently with
plasmepsin2/3 amplification status four mutations crt gene (thr93ser, 
his97tyr, phe145ile, ile218phe). compared results previous
traci trial 2011-13, prevalence molecular markers artemisinin
resistance (kelch13 cys580tyr mutations) piperaquine resistance
(plasmepsin2/3 amplifications crt mutations) increased substantially in
the greater mekong subregion past decade.
interpretation: dihydroartemisinin-piperaquine treating malaria
effectively across eastern greater mekong subregion. highly drug-resistant 
p falciparum co-lineage evolving, acquiring new resistance mechanisms, and
spreading. accelerated elimination p falciparum malaria region is
needed urgently, prevent spread avoid potential global health
emergency.
funding: uk department international development, wellcome trust, bill &
melinda gates foundation, medical research council, national institutes of
health.

copyright © 2019 author(s). published elsevier ltd. open access
article cc by-nc-nd 4·0 license. published elsevier ltd.. rights
reserved.

doi: 10.1016/s1473-3099(19)30391-3 
pmcid: pmc6715822
pmid: 31345710  [indexed medline]

